Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 4/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270250 | 0.87 | CYP3A4 (0.35) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL270368 | 0.80 | ESR1 (0.31) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL268906 | 0.68 | ESR1 (0.31) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL164931 | 0.68 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL11675272 | 0.68 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL2697473 | 0.68 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL7101958 | 0.68 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL6939765 | 0.66 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL7113981 | 0.66 | TDP1 (0.45) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL4973930 | 0.66 | TDP1 (0.45) | CYP3A4TDP1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134035-B2 | Preparation of asymmetric anthracene derivatives and organic electroluminescent device using same | DOOSAN CORPORATION (KR) | 2012-03-13 | — | — | US | disclosed |
| US-20110065924-A1 | PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | DOOSAN CORPORATION (KR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065924-A1 | PREPARATION OF ASYMMETRIC ANTHRACENE DERIVATIVES AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | AKR7A2, ACMSD, ALKBH3 | CYP3A4 215/4885TDP1 3492/4885ESR1 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.